Drug loaded polymeric nanoparticles and methods of making and using same

Patent metadata

Field	Value
Publication number	US-9872913-B2
Application number	US-201615161785-A
Country	US
Kind code	B2
Filing date	May 23, 2016
Priority date	Jun 16, 2008
Publication date	Jan 23, 2018
Grant date	Jan 23, 2018

Abstract

The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.

First claim

The invention claimed is:

1. A method of preparing a plurality of therapeutic nanoparticles, comprising:
combining a therapeutic agent, a first polymer bound to a ligand, and a second polymer, with an organic solvent to form a first organic phase having about 5 to about 50% solids;
combining the first organic phase with a first aqueous solution to form a second phase;
emulsifying the second phase to form an emulsion phase;
quenching the emulsion phase to form a quenched phase at least partially at a temperature of 5° C. or less;
adding a drug solubilizer to the quenched phase to form a solubilized phase of unencapsulated therapeutic agent; and
sterile filtering the solubilized phase to recover the therapeutic nanoparticles, thereby forming a slurry of therapeutic nanoparticles having a diameter of about 80 nm to about 150 nm.

2. The method of claim 1 , wherein emulsifying the second phase comprises:
emulsifying the second phase to form a coarse emulsion, and
emulsifying the coarse emulsion to form a fine emulsion phase.

3. The method of claim 2 , wherein the organic solvent comprises a solvent chosen from: ethyl acetate, benzyl alcohol, methylene chloride, chloroform, toluene, methyl ethyl ketone, dimethyl formamide, dimethyl sulfoxide, acetone, acetonitril, acetic acid, polyoxyethylene 20 sorbitan monooleate (Tween 80 )and sorbitan monooleate (Span 80), and combinations of two or more thereof.

4. The method of claim 2 , wherein the first aqueous solution comprises a reagent chosen from: sodium cholate, ethyl acetate, benzyl alcohol or combinations thereof.

5. The method of claim 2 , wherein emulsifying the second phase comprises using a rotor stator homogenizer, probe sonicator, stir bar, or high pressure homogenizer.

6. The method of claim 1 , wherein quenching is performed at least partially at about 0° C. to about 5° C.

7. The method of claim 1 , wherein the quench:emulsion ratio is about 8:1 to about 5:1.

8. The method of claim 1 , wherein filtering comprises filtering at a first temperature of about 0° C. to about 5° C., and further comprises filtering at a second temperature of about 20° C. to about 30° C.

9. The method of claim 8 , wherein filtering comprises processing about 1 to about 6 diavolumes at about 0° C. to about 5° C. and processing at least one diavolume at about 20° C. to about 30° C.

10. The method of claim 9 , wherein the second polymer is a poly (lactic) acid-block-poly(ethylene)glycol copolymer (PLA-PEG), and the first polymer is a PLA-PEG Ligand, wherein the ligand is covalently bound to the PEG, wherein the ligand is represented by the formula:

and the ligand has a molecular weight of about 100 g/mol to about 500 g/mol.

11. The method of claim 1 , wherein the therapeutic agent is a taxane.

12. The method of claim 1 , wherein filtering comprises using a tangential flow filtration system.

13. The method of claim 1 , wherein the second polymer is a PLA-PEG, and the first polymer is a PLA-PEG-Ligand, wherein the ligand is covalently bound to the PEG.

14. The method of claim 1 , wherein the ligand has a molecular weight of about 100 g/mol to about 500 g/mol.

15. The method of claim 1 , wherein the second polymer is a PLA-PEG; and the first polymer is a PLA-PEG-Ligand, wherein the ligand is covalently bound to the PEG, wherein the ligand is represented by the formula:

and the ligand has a molecular weight of about 100 g/mol to about 500 g/mol.

Assignees

• Pfizer

Inventors

• Troiano Greg
• Figa Michael
• Sabnis Abhimanyu

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P13/08

  of the prostate · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title